Skip to main content

Table 2 Haemodynamic parameters

From: Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study

 

SScPAH

N= 5

IPAH

N= 9

PVOD

N= 6

mRpa, mmHg

10 (6 to 18)

(n = 4)

11(7 to 23)

(n = 5)

10 (5 to 15)

(n = 5)

sPpa, mmHg

78 (70 to 101)

(n = 5)

100 (62 to 109)

(n = 9)

76 (58 to 100)

(n = 6)

mPpa, mmHg

55 (43 to 71)

(n = 5)

55 (43 to 76)

(n = 7)

49 (45 to 70)

(n = 6)

PCWP,mmHg

9 (5 to 12)

(n = 5)

7 (1 to 12)

(n = 7)

5 (5 to 11)

(n = 6)

PVR,

dynes·s · cm-5

1054 (627 to 3278) (n = 4)

957 (916 to 1587) (n = 6)

750 (479 to 1483) (n = 7)

CI, l/min·m2

2.2 (1.1 to 2.9)

(n = 7)

2.4 (1.3 to 3.2)

(n = 8)

2.6 (1.9 to 3.1)

(n = 6)

FEV1, %

92 (77 to 97) (n = 4)

80 (56 to 111)

(n = 8)

82 (74 to 95) (n = 6)

TLC, %

87 (81 to 115)

(n = 3)

94 (78 to 113)

(n = 9)

90 (81 to 105)

(n = 6)

VC, %

99 (88 to 120)

(n = 4)

87 (58 to 119)

(n = 8)

*

TLCO, %

35 (26 to 57)

(n = 4)

60 (52 to 90)

(n = 8)

49 (20 to 69)

(n = 6)

  1. Values expressed as median (range) or otherwise as stated. * not available
  2. CI, cardiac index; FEV1 %, percentage predicted of forced expiratory volume; IPAH, idiopathic PAH; mRpa, mean right atrial pressure; PCWP, pulmonary capillary wedge pressure; PVOD, pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; sPpa, mPpa, systolic, mean pulmonary artery pressures; SScPAH, systemic sclerosis-associated pulmonary arterial hypertension (PAH); TLC %, percentage of predicted total long capacity; TLCO %, percentage predicted of transfer factor of the lung for carbon monoxide; VC, percentage predicted of vital capacity.